TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Mink Therapeutics
MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025

MiNK Therapeutics presented clinical results showing promising immune cell therapy agenT-797 demonstrated durable responses and immune reactivation in patients with checkpoint-resistant solid tumors, with some patients experiencing complete remission lasting over two years.

Insights
TMO   positive

Offers wide-ranging CDMO services including API development, biologics, and gene therapy manufacturing


INKT   positive

Reported breakthrough clinical results with agenT-797, showing durable responses across multiple cancer types, potential to overcome treatment resistance, and favorable safety profile